PMID- 37702096
OWN - NLM
STAT- MEDLINE
DCOM- 20240415
LR  - 20240415
IS  - 1443-1661 (Electronic)
IS  - 0915-5635 (Linking)
VI  - 36
IP  - 4
DP  - 2024 Apr
TI  - Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for 
      pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis.
PG  - 395-405
LID - 10.1111/den.14681 [doi]
AB  - OBJECTIVE: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has 
      been constantly increasing, particularly in the treatment of pancreatic 
      neuroendocrine neoplasms (pNENs). While emerging data in this field are 
      accumulating, we aimed to assess the pooled efficacy and safety of EUS-RFA for 
      pNENs. METHODS: The PubMed/Medline, Embase, and Cochrane Library databases search 
      was conducted to identify studies reporting EUS-RFA of pNENs with outcomes of 
      interest (efficacy and safety). The primary outcome was radiological response. 
      Efficacy was assessed by the pooled clinical response rate, whereas safety was 
      assessed by the pooled adverse events (AEs) rate. Heterogeneity was assessed 
      using I(2). Pooled estimates and the 95% confidence interval (CI) were calculated 
      using a random-effect model. RESULTS: Eleven studies involving 292 patients were 
      included. The pooled technical success rate was 99.2% (95% CI 97.9-99.9%), with 
      no heterogeneity. The pooled complete radiological response was 87.1% (95% CI 
      80.1-92.8%). The pooled partial response was 11.4% (95% CI 6.2-18.1%). The pooled 
      clinical response rate for functional pNENs was 94.9% (95% CI 90.7-97.9%), with 
      no heterogeneity. The pooled incidence of AEs was 20.0% (95% CI 14.0-26.7%); most 
      AEs were mild to moderate in grade, while the pooled incidence of severe AEs was 
      0.9% (95% CI 0.2-2.3%). The most common AEs were transient mild abdominal pain in 
      19 patients (6.5%), and mild to moderate pancreatitis in 23 patients (7.9%). No 
      cases of mortality were reported. CONCLUSION: Endoscopic ultrasound-guided 
      radiofrequency ablation resulted on a feasible approach for pNENs treatment, with 
      excellent technical success, high radiological and clinical response, and 
      acceptable AE rate.
CI  - (c) 2023 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, 
      Ltd on behalf of Japan Gastroenterological Endoscopy Society.
FAU - Khoury, Tawfik
AU  - Khoury T
AUID- ORCID: 0000-0001-6059-3854
AD  - Department of Gastroenterology, Galilee Medical Center, Nahariya, Israel.
AD  - Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
FAU - Sbeit, Wisam
AU  - Sbeit W
AD  - Department of Gastroenterology, Galilee Medical Center, Nahariya, Israel.
AD  - Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
FAU - Fusaroli, Pietro
AU  - Fusaroli P
AD  - Gastroenterology Unit, Hospital of Imola, University of Bologna, Bologna, Italy.
FAU - Campana, Davide
AU  - Campana D
AD  - Department of Experimental, Diagnostic and Specialty Medicine, 
      Sant'Orsola-Malpighi University Hospital, ENETS Center of Excellence, Bologna, 
      Italy.
FAU - Brighi, Nicole
AU  - Brighi N
AD  - Department of Medical Oncology, IRCCS Romagna Institute for the Study of Tumors 
      "Dino Amadori", Meldola, Italy.
FAU - Napoleon, Bertrand
AU  - Napoleon B
AD  - Department of Gastroenterology, Jean Mermoz Private Hospital, Ramsay Health, 
      Lyon, France.
FAU - Lisotti, Andrea
AU  - Lisotti A
AUID- ORCID: 0000-0002-7724-7402
AD  - Gastroenterology Unit, Hospital of Imola, University of Bologna, Bologna, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20231011
PL  - Australia
TA  - Dig Endosc
JT  - Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy 
      Society
JID - 9101419
SB  - IM
MH  - Humans
MH  - *Pancreatic Neoplasms/surgery/complications
MH  - Endosonography/methods
MH  - *Radiofrequency Ablation/adverse effects
MH  - *Pancreatitis/etiology
MH  - Ultrasonography, Interventional
OTO - NOTNLM
OT  - efficacy
OT  - meta-analysis
OT  - neuroendocrine tumor
OT  - pancreas
OT  - safety
EDAT- 2023/09/13 06:42
MHDA- 2024/04/15 06:42
CRDT- 2023/09/13 05:28
PHST- 2023/07/04 00:00 [received]
PHST- 2023/09/10 00:00 [accepted]
PHST- 2024/04/15 06:42 [medline]
PHST- 2023/09/13 06:42 [pubmed]
PHST- 2023/09/13 05:28 [entrez]
AID - 10.1111/den.14681 [doi]
PST - ppublish
SO  - Dig Endosc. 2024 Apr;36(4):395-405. doi: 10.1111/den.14681. Epub 2023 Oct 11.